Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | HPGD | P15428 | 4/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | THRA | P10827 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13702958 | 0.85 | LMNA (0.50) | POLBALDH1A1KDM4EHPGDMAPT | |
| SCHEMBL491024 | 0.81 | POLB (0.50) | POLBALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL13064939 | 0.80 | TAAR1 (0.59) | POLBALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL6644153 | 0.78 | MTNR1A (0.45) | KDM4ESMN1; SMN2 | |
| SCHEMBL2390684 | 0.77 | FFAR1 (0.49) | POLBFFAR1THRATHRB | |
| SCHEMBL31674114 | 0.77 | GPR17 (0.49) | POLBALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL490401 | 0.77 | FFAR1 (0.56) | POLBFFAR1THRATHRB | |
| SCHEMBL18606621 | 0.77 | GPR17 (0.59) | GPR17PKMFFAR1THRATHRB | |
| SCHEMBL4732348 | 0.77 | GPR17 (0.46) | ALDH1A1HPGDHSD17B10GPR17MAPT | |
| SCHEMBL9037504 | 0.76 | POLB (0.65) | POLBALDH1A1KDM4EHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239897-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239897-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239897-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-7550480-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550480-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550480-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-23 | — | — | US | disclosed |
| US-20060211727-A1 | Novel compounds | GLAXOSMITHKLINE LLC | 2006-09-21 | — | — | US | disclosed |
| US-6809199-B2 | ANTIINFLAMMATORY AGENTS; RHEUMATIC DISEASES | MERCK & CO., INC. | 2004-10-26 | — | — | US | disclosed |
| EP-1345603-A4 | (HALO-BENZO CARBONYL)HETEROCYCLO FUSED PHENYL P38 KINASE INHIBITING AGENTS | MERCK & CO INC (US) | 2004-09-08 | — | — | EP | disclosed |
| EP-1345603-A1 | (HALO-BENZO CARBONYL)HETEROCYCLO FUSED PHENYL P38 KINASE INHIBITING AGENTS | Merck & Co., Inc. (US) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002058695-A9 | (HALO-BENZO CARBONYL)HETEROCYCLO FUSED PHENYL P38 KINASE INHIBITING AGENTS | MERCK & CO INC (US) | 2003-09-12 | — | — | WO | disclosed |
| US-20030092712-A1 | (Halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents | MERCK SHARP & DOHME CORP. | 2003-05-15 | — | — | US | disclosed |
| WO-2002058695-A1 | (HALO-BENZO CARBONYL)HETEROCYCLO FUSED PHENYL P38 KINASE INHIBITING AGENTS | MERCK & CO., INC. (US) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239897-A1 | NOVEL COMPOUNDS | MAPKAPK2, CREBBP, MAPK1 | POLB 3347/4885ALDH1A1 3499/4885KDM4E 3591/4885 |
| US-20030092712-A1 | (Halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents | MAPK1, MAPK7, MAPKAPK2 | POLB 2327/4885ALDH1A1 867/4885KDM4E 3410/4885 |
| US-20060211727-A1 | Novel compounds | MAPKAPK2, CREBBP, MAPK1 | POLB 3347/4885ALDH1A1 3499/4885KDM4E 3591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.